Could CAR-Ts Roll Into The Community Setting?

Study Looks At Potential Feasibility Of Cell Therapy Beyond Academia

While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space.

Research presented at ISPOR explored the feasibility of CAR-T for DLBCL in community oncology settings • Source: Shutterstock

For as long as CAR-T cell therapies have existed, their complex management and toxicity profiles have largely confined their use to large, academic medical centers as well as hospital systems with similar levels of infrastructural sophistication, and they have yet to really trickle down to community hematology/oncology settings. But new research looks in part at how that could be feasible.

Cardinal Health, Inc.'s Specialty Solutions division presented multiple abstracts at the International Society for Pharmacoeconomics and Outcomes Research meeting, which took place 15-18 May. The main purpose was to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

27 May 2025

• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Progress In The Effort To Improve Outcomes In SCLC

26 May 2025

• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Merus Bispecific Impresses In Head And Neck Cancer

23 May 2025

• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.